Add BrightSurf on Google Email

Cancer cells may sense immune surveillance and actively adapt

Researchers propose a new theory on how cancer cells actively adapt to evade the immune system, losing and gaining tumor-associated antigens. This adaptation makes it difficult for immunotherapies to target cancer cells effectively, but may also create new vulnerabilities that can be therapeutically targeted.

SourceeLife·JournaleLife·DateApr 25, 2023

Luring the virus into a trap

Heidelberg researchers have identified key proteins that can prevent the formation of fusion pores, allowing viruses like influenza A and Ebola to be trapped in a lipid membrane. This breakthrough could lead to new approaches for preventing infections with these highly infectious viruses.

SourceHeidelberg University·JournalThe EMBO Journal·TypeComputational simulation/modeling·DateApr 25, 2023

How cancer evades immune system detection and spreads

Research discovers how cancer cells evade immune system detection and metastasize in the body. Pre-metastatic cells and exhausted CD8+ cells are identified as key players in this process. The study explores ways to target these pathways and activate immune responses to block metastasis.

SourceSingHealth·JournalNature Communications·DateApr 10, 2023

How to achieve a functional cure for chronic hepatitis B

A study published in Journal of Hepatology found that some patients with chronic hepatitis B can achieve sustained immune control by discontinuing antiviral therapy after four years. This suggests a potential cure for the disease, which affects an estimated 350 million people worldwide.

SourceUniversität Leipzig·JournalJournal of Hepatology·TypeRandomized controlled/clinical trial·DateMar 30, 2023

Trinity and University of Manchester researchers tackle parasitic worms that infect millions worldwide

A recent study published in the journal Immunity has shed light on the immune response to parasitic worm infection, revealing a critical role for T cells and macrophages. The research team identified specific signaling molecules that control the development of tissue-resident macrophages, which are essential for eliminating the infection.

SourceTrinity College Dublin·JournalImmunity·TypeExperimental study·DateMar 30, 2023

Immune Development in Early Life (IDEAL) study to identify new approaches for predicting and preventing childhood disease

An international project aims to discover modifiable cellular and molecular pathways of the developing infant immune system to improve infant vaccine responsiveness and prevent respiratory disease. By analyzing infants' immune systems from birth to five years old, researchers hope to identify biomarkers that predict vaccine responsiven...

We've learned a lot from lymphocytic choriomeningitis virus—now the time has come to fight it

Researchers at La Jolla Institute for Immunology have developed a high-resolution view of the LCMV glycoprotein, revealing its structure and potential vulnerabilities. The breakthrough enables the development of an engineered antibody that can prevent LCMV disease, offering a new route to treatment.

SourceLa Jolla Institute for Immunology·JournalCell Chemical Biology·TypeExperimental study·DateMar 28, 2023

Potential relief for osteoarthritis moves to clinical trial after animal studies

Researchers have found a potential treatment for osteoarthritis by targeting the GP130 immune receptor, which causes hyper-inflammation in joints. The new compound R805/CX-011 showed promising results in animal studies, reducing joint pain and stiffness, and may lead to Phase 1 and 2A clinical trials.

SourceKeck School of Medicine of USC·JournalScience Translational Medicine·TypeExperimental study·DateMar 22, 2023

First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases

Researchers at Brigham and Women's Hospital tested a new nasal monoclonal antibody treatment, Foralumab, which decreased inflammatory markers and lung inflammation in patients with COVID-19. The treatment also showed similar effects in multiple sclerosis patients, suggesting its potential use for treating other diseases.

SourceBrigham and Women's Hospital·JournalProceedings of the National Academy of Sciences·TypeObservational study·DateMar 8, 2023

The marathon runners of the immune system

A biological messenger called interleukin-33 (IL-33) plays a crucial role in maintaining cytotoxic T cells' 'marathon runner' state, allowing them to provide sustained immunity against chronic infections. This finding has implications for improving treatment of hepatitis C and cancer immunotherapy.

SourceUniversity of Basel·JournalImmunity·TypeExperimental study·DateMar 6, 2023

Newly identified personalized immunotherapy combination treats an aggressive form of advanced prostate cancer

Researchers discovered a new personalized immunotherapy combination that treats aggressive forms of advanced prostate cancer. By blocking PD-1-expressing macrophages and Wnt/β-catenin pathway activation, the therapy significantly improves response rates in PTEN-deficient cancers.

SourceUniversity of Chicago Medical Center·JournalClinical Cancer Research·TypeExperimental study·DateMar 2, 2023

New treatment for COVID-19 is made from plants

Researchers at Arizona State University describe an innovative therapy using transient expression in tobacco plants to produce a monoclonal antibody against SARS-CoV-2. This class 4 mAb provides key advantages over existing treatments, including mutation resistance and universal protection against emerging variants.

SourceArizona State University·JournalPlant Biotechnology Journal·TypeExperimental study·DateFeb 25, 2023

CHOP researchers identify molecules that optimize immune presentation of antigens across the human population

CHOP researchers have identified variants of a chaperone molecule that can enhance the loading of peptides across different HLA types, which could be used in cell therapy and immunization applications. The study found that chicken-derived TAPBPR proteins can react with multiple HLA allotypes and stabilize the empty MHC-I groove, boosti...

SourceChildren's Hospital of Philadelphia·JournalScience Advances·DateFeb 24, 2023

New research reveals possible COVID vaccine blood clot connection

A new Australian study found fundamental differences in how the AstraZeneca and Pfizer COVID-19 vaccines impact the immune system, with some people receiving more effective protection than others. The study revealed a potential explanation for the connection between the AstraZeneca vaccine and blood clotting cases.

SourceFlinders University·JournalCell Reports Medicine·TypeRandomized controlled/clinical trial·DateFeb 21, 2023

Pungent ginger compound puts immune cells on heightened alert

A recent study by Leibniz Institute for Food Systems Biology at TUM found that a pungent ginger compound puts immune cells on heightened alert. The compound, [6]-gingerol, stimulates white blood cells via the TRPV1 receptor, which plays a role in the perception of painful heat stimuli and spiciness.

SourceLeibniz-Institut für Lebensmittel-Systembiologie an der TU München·JournalMolecular Nutrition & Food Research·TypeExperimental study·DateFeb 14, 2023

Myalgic encephalomyelitis/chronic fatigue syndrome is associated with distinct changes in the microbiome and gut metabolites

Two studies reveal that ME/CFS is associated with reduced levels of butyrate-producing microbes and differences in gut metabolites. Researchers found distinct changes in the microbiome of patients with short-term and long-term ME/CFS, suggesting a potential link between gut dysbiosis and the disease's severity.

SourceCell Press·JournalCell Host & Microbe·TypeExperimental study·DateFeb 8, 2023

Molecular machines could treat fungal infections

Researchers at Rice University have developed light-activated nanoscale drills that can kill pathogenic fungi, providing a potential new treatment option for fungal infections. The molecular machines target the mitochondria of fungal cells, disrupting cellular metabolism and leading to cell death.

SourceRice University·JournalAdvanced Science·TypeExperimental study·DateFeb 1, 2023

Immunocompromised patients remain at higher risk of COVID-19 death in hospital

A UK study using data from over 150,000 hospitalized patients found that immunocompromised individuals had a 44% higher risk of death compared to those with normal immune systems. The gap in mortality rates widened for immunocompromised patients over time, highlighting the need for targeted interventions such as antiviral treatments an...

SourceUniversity of Liverpool·JournalPLOS Medicine·TypeData/statistical analysis·DateFeb 1, 2023

Pusan National University researchers uncover novel gene that regulates leukemia development and progression

Pusan National University researchers have identified a novel gene, SURF4, that regulates cell death and differentiation in acute myeloid leukemia (AML). The study found that suppressing SURF4 expression increases cell differentiation, cell death, and accumulation of ROS, leading to arrested tumor growth in mice.

SourcePusan National University·JournalCancer Communications·TypeExperimental study·DateJan 31, 2023

Transforming the way cancer vaccines are designed and made

Researchers developed a new way to increase vaccine potency by changing the structural location of antigens and adjuvants. This approach, called 'rational vaccinology,' allows for precise dosing and tailored presentation of vaccine components, leading to improved immune response and cancer cell targeting.

SourceNorthwestern University·JournalNature Biomedical Engineering·TypeExperimental study·DateJan 31, 2023

LJI scientists uncover the structure and function of Inmazeb, the first FDA-approved drug for Ebola virus infection

Researchers at La Jolla Institute for Immunology have discovered the detailed mechanism of action of Inmazeb, a three-antibody cocktail designed to combat Ebola virus infection. The study reveals new information about how the drug interacts with the virus and its potential effectiveness against additional species of Ebolavirus.

SourceLa Jolla Institute for Immunology·JournalCell Host & Microbe·TypeExperimental study·DateJan 30, 2023